| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.22B | 23.63B | 20.71B | 20.35B | 19.04B | 16.97B |
| Gross Profit | 7.93B | 8.01B | 6.68B | 6.27B | 6.27B | 5.56B |
| EBITDA | 4.66B | 3.95B | 3.14B | 2.96B | 3.29B | 2.62B |
| Net Income | 2.29B | 2.47B | 1.91B | 1.68B | 2.05B | 1.50B |
Balance Sheet | ||||||
| Total Assets | 26.93B | 27.00B | 27.92B | 26.51B | 25.88B | 24.94B |
| Cash, Cash Equivalents and Short-Term Investments | 8.28B | 7.92B | 6.54B | 5.93B | 5.54B | 5.32B |
| Total Debt | 642.70M | 17.27M | 21.37M | 23.94M | 26.99M | 20.00M |
| Total Liabilities | 4.75B | 5.10B | 4.81B | 4.61B | 4.39B | 4.41B |
| Stockholders Equity | 22.18B | 21.90B | 23.11B | 21.90B | 21.49B | 20.53B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.20B | 1.13B | 538.07M | 1.55B | 1.84B |
| Operating Cash Flow | 0.00 | 3.59B | 1.84B | 947.42M | 1.79B | 2.41B |
| Investing Cash Flow | 0.00 | 182.80M | -281.44M | 716.59M | -604.65M | -1.46B |
| Financing Cash Flow | 0.00 | -3.68B | -883.04M | -1.18B | -862.55M | -355.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥33.81B | 12.59 | ― | 1.90% | 2.15% | 16.14% | |
75 Outperform | ¥56.49B | 13.24 | ― | 2.22% | 5.17% | 79.36% | |
75 Outperform | ¥51.10B | 18.81 | ― | 1.92% | -0.86% | 17.65% | |
74 Outperform | ¥30.63B | 16.36 | ― | 3.24% | 1.83% | -8.54% | |
70 Outperform | ¥106.03B | 20.80 | ― | 1.24% | 8.78% | 19.37% | |
65 Neutral | ¥37.53B | 19.61 | ― | 2.37% | -11.70% | -54.82% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
For the nine months ended December 31, 2025, Ishihara Chemical reported a 2.8% year-on-year decline in net sales to ¥17.5 billion, but operating profit and ordinary profit were essentially flat, and profit attributable to owners of parent rose 3.2% to ¥2.06 billion, driving basic earnings per share up to ¥151.14. The company’s financial position strengthened, with total assets rising to ¥28.4 billion and the equity ratio improving to 83.6%, and it confirmed unchanged guidance for the full fiscal year to March 2026, targeting modest growth in revenue and profit alongside a planned increase in annual dividends to ¥44 per share, signaling continued confidence and commitment to shareholder returns despite softer top-line growth.
The most recent analyst rating on (JP:4462) stock is a Buy with a Yen2704.00 price target. To see the full list of analyst forecasts on Ishihara Chemical Company,Ltd. stock, see the JP:4462 Stock Forecast page.
Ishihara Chemical Co., Ltd. announced changes in its directors’ responsibilities, effective April 1, 2026, as resolved in their Board of Directors meeting. Akihiko Fujimoto will continue as Representative Director and President, while Yoshitaka Ito will take on the role of Director, Chief Sales Officer, and General Manager of the Industrial Chemicals Department. These changes are expected to streamline leadership roles and potentially enhance operational efficiency.
The most recent analyst rating on (JP:4462) stock is a Buy with a Yen2310.00 price target. To see the full list of analyst forecasts on Ishihara Chemical Company,Ltd. stock, see the JP:4462 Stock Forecast page.